Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Uniqure’s accelerated approval hopes take a hit
Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.
Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.